Bilfinger

Company Update:
Five weeks after confirming guidance, Bilfinger has cut FY26 adjusted EBITA guidance to €264m at midpoint, 20% below post-Q2 consensus (€328m). A separate €75m restructuring charge takes reported EBITA to approximately €187m, 43% below consensus.

The anticipated H2 recovery has failed to materialize: implied H2 adjusted EBITA is down approximately 34% versus consensus, reflecting investment delays, persistent underutilization and adverse mix.

Moreover, there is an issue with FY27. Consensus of €378m requires a 43% earnings rebound, while Agile's €75m annual savings will only be fully effective from 2028. Even assuming the entire benefit arrives a year early, EBITA would remain 10% below FY27 consensus. We expect a negative market reaction.

Expert Opinion:
This is worrying. Bilfinger says H2 business is “considerably below expectations.” Our first reaction is of higher caution as this may be worse than a simple Middle East-related revenue warning. The revenue downgrade is modest, but the margin downgrade is large, suggesting significant operating leverage/underutilisation and mix deterioration.  Interestingly, Bilfinger maintains its 2030 targets of 8–10% annual revenue growth including M&A, 8–9% EBITA margin and ≥90% cash conversion but we suspect market will view these as much more demanding than they looked 24 hours ago. 

We suspect consensus will adjust down substantially. No reason to jump in the name yet. 


For daily updates, subscribe to our newsletter and for detailed information, reach out to us at sales@alphavalue.eu